Bacterial extracts cultured in thermal waters comprising anti-redness agents

US9770474B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9770474-B2
Application numberUS-17510808-A
CountryUS
Kind codeB2
Filing dateJul 17, 2008
Priority dateJul 17, 2007
Publication dateSep 26, 2017
Grant dateSep 26, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Red blotches on the skin such as those associated with environmental stresses, or red blotches associated with a skin disorder, for example those occurring during rosacea, are treated/reduced by administering to individuals afflicted therewith, thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured in a medium which includes at least one non-sulfurous mineral and/or thermal water, e.g., an extract derived from the bacterium Vitreoscilla filiformis , in particular the strain ATCC 15551, cultured in a medium enriched with water from La Roche Posay.

First claim

Opening claim text (preview).

What is claimed is: 1. A method of treating erythema in a human suffering from atopic dermatitis and/or erythema in a human suffering from seborrheic dermatitis, the method comprising administering an effective amount of an extract of Vitreoscilla filiformis to the human in need thereof to treat the erythema in a human suffering from atopic dermatitis and/or the erythema in a human suffering from seborrheic dermatitis, wherein the Vitreoscilla filiformis is cultured in a medium which comprises at least one non-sulfurous mineral and/or thermal water. 2. The method of claim 1 , wherein said thermal water is from La Roche Posay. 3. The method of claim 1 , wherein said at least one non-sulfurous mineral and/or thermal water has a total mineral content ranging from 400 to 900 mg/l. 4. The method of claim 1 , wherein said at least one non-sulfurous mineral and/or thermal water has a total concentration of carbonates and of bicarbonates of at least 150 mg/l and a concentration of silicon oxide of at least 6 mg/l. 5. The method of claim 1 , wherein said thermal water is from Vittel, from the Vichy basin, from Uriage, from La Bourboule, from Enghien-les-Bains, from Saint-Gervais-les-Bains, from Néris-les-Bains, from Allevard-les-Bains, from Digne, from Maizières, water from Neyrac-les-Bains, from Lons-le-Saunier, from Eaux-Bonnes, from Rochefort, from Saint Christau, from Les Fumades or from Tercis-les-Bains. 6. The method of claim 3 , wherein said at least one non-sulfurous mineral and/or thermal water has a concentration of calcium ions of at least 100 mg/l. 7. The method of claim 1 , said Vitreoscilla filiformis extract is from 0.001 to 20% by weight of the total weight of a composition comprised thereof. 8. The method of claim 1 , further comprising administering to said human at least one agent selected from the group consisting of retinoids, corticosteroids, free-radical scavengers, alpha-hydroxy, alpha-keto acids, ion channel blockers, wetting agents, depigmenting agents, emollients, moisturizers, anti-seborrheic, anti-acne agents, antibiotics, anti-fungal agents, agents for promoting hair regrowth, non-steroidal anti-inflammatories, carotenoids, anti-psoriatic agents, preservatives, stabilizers, moisture regulators, emulsifiers, ultraviolet A screens, ultraviolet B screens, and antioxidants. 9. The method of claim 1 , further comprising administering to said human at least one agent selected from the group consisting of vasoprotector agents that act on the microcirculation, vasoconstrictor agents that act on the microcirculation, a substance that gives the skin a color, and an active agent for treating rosacea. 10. The method of claim 9 , further comprising administering to said human a green colorant. 11. The method of claim 1 , wherein the culture medium consists essentially of water from La Roche Posay, autolyzed yeast extract, plant peptone, anhydrous glucose, Heller microelements and calcium chloride.

Assignees

Inventors

Classifications

  • Antiseborrheics · CPC title

  • Drugs for dermatological disorders · CPC title

  • Mineral waters; Sea water · CPC title

  • A61K35/74Primary

    Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title

  • Preparations containing skin colorants, e.g. pigments (preparations in powder form A61Q1/12) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9770474B2 cover?
Red blotches on the skin such as those associated with environmental stresses, or red blotches associated with a skin disorder, for example those occurring during rosacea, are treated/reduced by administering to individuals afflicted therewith, thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured in a medium which includes at lea…
Who is the assignee on this patent?
Gueniche Audrey, Breton Lionel, Oreal
What technology area does this patent fall under?
Primary CPC classification A61K35/74. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).